Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions

Bibliography

• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008;48:311-21
   PubMed Web of Science ®Google Scholar
• Lee NH. Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents. Anticancer Agents Med Chem 2010;10:583-92
   PubMed Web of Science ®Google Scholar
• Giorgi MA, Caroli C, Arazi HC, Di GG. Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opin Pharmacother 2011;12:1499-509
   PubMed Web of Science ®Google Scholar
• Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 2008;9:597-624
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004;447:653-65
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008;38:778-801
   PubMed Web of Science ®Google Scholar
• Svoboda M, Riha J, Wlcek K, Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab 2011;12:139-53
   PubMed Web of Science ®Google Scholar
• Kanai N, Lu R, Bao Y, Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol 1996;270:F319-25
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Nozawa T, Imai K, Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003;306:703-8
   PubMed Web of Science ®Google Scholar
• Leuthold S, Hagenbuch B, Mohebbi N, Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 2009;296:C570-82
   PubMed Web of Science ®Google Scholar
• Nozawa T, Imai K, Nezu J, Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004;308:438-45
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Pharmacol Rev2010;62:1-96
   Google Scholar
• Tamai I, Nezu J, Uchino H, Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000;273:251-60
   PubMed Web of Science ®Google Scholar
• Cheng X, Maher J, Chen C, Klaassen CD. Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab Dispos 2005;33:1062-73
   PubMed Web of Science ®Google Scholar
• Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234:4-33
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9
   PubMed Web of Science ®Google Scholar
• Ho RH, Choi L, Lee W, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007;17:647-56
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006;79:427-39
   PubMed Web of Science ®Google Scholar
• Tachibana-Iimori R, Tabara Y, Kusuhara H, Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004;19:375-80
   PubMedGoogle Scholar
• Link E, Parish S, Armitage J, SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008;359:789-99
   PubMed Web of Science ®Google Scholar
• Brunham LR, Lansberg PJ, Zhang L, Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2011; published online 18 Jan 2011; doi: 10.1038/tpj.2010.92
   PubMed Web of Science ®Google Scholar
• Voora D, Shah SH, Spasojevic I, The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16
   PubMed Web of Science ®Google Scholar
• Pizzagalli F, Varga Z, Huber RD, Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab 2003;88:3902-12
   PubMed Web of Science ®Google Scholar
• Hamada A, Sissung T, Price DK, Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14:3312-18
   PubMed Web of Science ®Google Scholar
• Yang M, Xie W, Mostaghel E, SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011;29:2565-73
   PubMed Web of Science ®Google Scholar
• Trevino LR, Shimasaki N, Yang W, Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009;27:5972-8
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276:35669-75
   PubMed Web of Science ®Google Scholar
• Lee W, Glaeser H, Smith LH, Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005;280:9610-17
   PubMed Web of Science ®Google Scholar
• Kacevska M, Ivanov M, Ingelman-Sundberg M. Perspectives on epigenetics and its relevance to adverse drug reactions. Clin Pharmacol Ther 2011;89:902-7
   PubMed Web of Science ®Google Scholar
• Imai S, Kikuchi R, Kusuhara H, Analysis of DNA methylation and histone modification profiles of liver-specific transporters. Mol Pharmacol 2009;75:568-76
   PubMed Web of Science ®Google Scholar
• Holla VR, Backlund MG, Yang P, Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) 2008;1:93-9
   PubMed Web of Science ®Google Scholar
• Ichihara S, Kikuchi R, Kusuhara H, DNA methylation profiles of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res 2010;27:510-16
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005;45:689-723
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Page RL, Zolty R, Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation 2005;111:113-17
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore) 1987;66:309-16
   PubMed Web of Science ®Google Scholar
• Shitara Y, Itoh T, Sato H, Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003;304:610-16
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006;34:1229-36
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama D, Kusuhara H, Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res 2002;19:147-53
   PubMed Web of Science ®Google Scholar
• Treiber A, Schneiter R, Delahaye S, Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 2004;308:1121-9
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Iacona I, Campana C, Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993;25:2732-4
   PubMed Web of Science ®Google Scholar
• Hedman M, Neuvonen PJ, Neuvonen M, Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004;75:101-9
   PubMed Web of Science ®Google Scholar
• Ichimaru N, Takahara S, Kokado Y, Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001;158:417-23
   PubMed Web of Science ®Google Scholar
• Poels PJ, Gabreels FJ. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 1993;95:175-92
   PubMed Web of Science ®Google Scholar
• Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95
   PubMed Web of Science ®Google Scholar
• Page RL, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 2005;111:230-9
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Leake BF, Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007;81:495-502
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bailey DG, Dresser GK, Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-70
   PubMed Web of Science ®Google Scholar
• Imanaga J, Kotegawa T, Imai H, The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics 2011;21:84-93
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-61
   PubMed Web of Science ®Google Scholar
• Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 1995;29:370-91
   PubMed Web of Science ®Google Scholar
• Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883-9
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 2009;613:119-27
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Fisher CD, Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic Fatty liver disease. Drug Metab Dispos 2011;39:1954-60
   PubMed Web of Science ®Google Scholar
• Lickteig AJ, Slitt AL, Arkan MC, Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis. Drug Metab Dispos 2007;35:402-9
   PubMed Web of Science ®Google Scholar
• Planchamp C, Montet X, Frossard JL, Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol 2005;40:187-94
   PubMed Web of Science ®Google Scholar
• Donner MG, Schumacher S, Warskulat U, Obstructive cholestasis induces TNF-alpha- and IL-1 -mediated periportal downregulation of Bsep and zonal regulation of Ntcp, Oatp1a4, and Oatp1b2. Am J Physiol Gastrointest Liver Physiol 2007;293:G1134-46
   PubMed Web of Science ®Google Scholar
• Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 2004;32:734-41
   PubMed Web of Science ®Google Scholar
• Li N, Klaassen CD. Role of liver-enriched transcription factors in the down-regulation of organic anion transporting polypeptide 4 (oatp4; oatplb2; slc21a10) by lipopolysaccharide. Mol Pharmacol 2004;66:694-701
   PubMed Web of Science ®Google Scholar
• Li N, Choudhuri S, Cherrington NJ, Klaassen CD. Down-regulation of mouse organic anion-transporting polypeptide 4 (Oatp4; Oatp1b2; Slc21a10) mRNA by lipopolysaccharide through the toll-like receptor 4 (TLR4). Drug Metab Dispos 2004;32:1265-71
   PubMed Web of Science ®Google Scholar
• Li N, Klaassen CD. Lipopolysaccharide-induced down-regulation of organic anion transporting polypeptide 4 (Oatp4; Slc21a10) is independent of tumor necrosis factor-alpha, Interleukin-1beta, interleukin-6, or inducible nitric oxide synthase. Toxicol Sci 2005;83:197-203
   PubMed Web of Science ®Google Scholar
• Cui Y, Konig J, Nies AT, Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest 2003;83:527-38
   PubMed Web of Science ®Google Scholar
• Libra A, Fernetti C, Lorusso V, Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther 2006;319:809-17
   PubMed Web of Science ®Google Scholar
• Monks NR, Liu S, Xu Y, Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OAT. Mol Cancer Ther 2007;6:587-98
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Jung D, Fried M, The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 2004;40:212-18
   PubMed Web of Science ®Google Scholar
• Zollner G, Wagner M, Fickert P, Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 2005;25:367-79
   PubMed Web of Science ®Google Scholar
• Pressler H, Sissung TM, Venzon D, Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS ONE 2011;6:e20372
   PubMed Web of Science ®Google Scholar
• Tsuboyama T, Onishi H, Kim T, Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging–correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010;255:824-33
   PubMed Web of Science ®Google Scholar
• Adverse Events Reporting System. U S Food and Drug Administration,2011. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070461.htm [Last accessed 25 August 2011]
   Google Scholar
• Davies EC, Green CF, Taylor S, Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 2009;4:e4439
   PubMed Web of Science ®Google Scholar
• Huang SM, Zhang L, Giacomini KM. The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA. Clin Pharmacol Ther 2010;87:32-6
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36
   PubMed Web of Science ®Google Scholar
• Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci USA 2010;107:9287-92
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Fisher CD, Canet MJ, Variations in ABC-transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 2011;39:2395-402
   PubMed Web of Science ®Google Scholar
• Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14:441-52
   PubMedGoogle Scholar
• Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-32
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011;31:147-56
   PubMed Web of Science ®Google Scholar
• Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91
   PubMed Web of Science ®Google Scholar
• He YJ, Zhang W, Chen Y, Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T > C polymorphism. Clin Chim Acta 2009;405:49-52
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9:19-33
   PubMed Web of Science ®Google Scholar
• Smith NF, Marsh S, Scott-Horton TJ, Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76-82
   PubMed Web of Science ®Google Scholar
• Laitinen A, Niemi M. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population. Basic Clin Pharmacol Toxicol 2011;108:9-13
   PubMed Web of Science ®Google Scholar